HealthDay By Robert Preidt
Friday, September 14, 2007
READ COMPLETE ARTICLE
FRIDAY, Sept. 14 (HealthDay News) — In a head-to-head trial, Swedish
researchers found that a pill called dabigatran etexilate (DE) is just as
effective as an injected drug, enoxaparin, in reducing the risk of blood clots
after total hip replacement surgery.
As reported in this week’s issue of The Lancet, the study included almost 3,500
hip replacement patients who received either oral DE at 220 milligrams daily, DE
at 150 milligrams daily, or an injection of enoxaparin at 40 milligrams once
daily, for 28 to 35 days.
Blood clots or death from all causes occurred in 53 of 880 (6 percent) of
patients on 220 milligrams DE, in 75 of 874 (8.6 percent) of patients on 150
milligrams DE, and in 60 of 897 (6.7 percent) of patients in the enoxaparin
The researchers found no significant differences in bleeding rates, frequency of
coronary events, or increases in liver enzyme concentrations between the three
groups of patients.
There were also no differences between the groups in terms of "reducing the risk
of total venous thromboembolism, and all-cause mortality after total hip
replacement," wrote the researchers from Sahlgrenska University Hospital in
The study was funded by Boehringer Ingelheim, the company that makes DE.
In an accompanying editorial, Dr. John Norrie of the Centre for Healthcare
Randomised Trials at the University of Aberdeen in Scotland, also notes that the
study did have methodological flaws, linked to missing data.